2 Promising Hepatitis B Drugs, 1 Clear Winner Among Investors
Investors eagerly awaiting updates from the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, simply referred to as the Liver Meeting, weren't disappointed when presentations began publishing online in mid-November. Some of the most intriguing drug candidates in the pharmaceutical industry's pipeline, treating conditions ranging from fatty liver disease to chronic hepatitis B (CHB), were on display.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Assembly Biosciences (NASDAQ: ASMB) were two companies that stoked investor interest heading into the meeting. Each is developing a treatment for CHB. Both had promising potential based on results published before the meeting. But investors appear to have coalesced around one of the drug candidates now that the meeting has ended.
Image source: Getty Images.
Source Fool.com
